NCT02528357View on ClinicalTrials.gov

GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)

PHASE1CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

September 11, 2015

Primary Completion Date

April 29, 2020

Study Completion Date

April 29, 2020

Conditions
Neoplasms
Interventions
DRUG

GSK3174998

Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to \<=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W

DRUG

Pembrolizumab

Pembrolizumab as 100 mg/4 milliliter (mL) solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W

Trial Locations (8)

10016

GSK Investigational Site, New York

10065

GSK Investigational Site, New York

37203

GSK Investigational Site, Nashville

77030

GSK Investigational Site, Houston

94805

GSK Investigational Site, Villejuif

02215

GSK Investigational Site, Boston

M5G 2M9

GSK Investigational Site, Toronto

1066 CX

GSK Investigational Site, Amsterdam

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY